BNP Paribas boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 8.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 48,416 shares of the company’s stock after purchasing an additional 3,865 shares during the period. BNP Paribas’ holdings in Johnson & Johnson were worth $12,912,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently made changes to their positions in JNJ. NWK Group Inc. acquired a new position in shares of Johnson & Johnson in the third quarter worth $7,418,000. Allianz SE lifted its position in shares of Johnson & Johnson by 5.8% during the third quarter. Allianz SE now owns 94,654 shares of the company’s stock worth $25,059,000 after purchasing an additional 5,216 shares during the last quarter. Texas Yale Capital Corp. lifted its holdings in Johnson & Johnson by 6.5% in the third quarter. Texas Yale Capital Corp. now owns 38,395 shares of the company’s stock worth $10,165,000 after acquiring an additional 2,358 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC boosted its stake in Johnson & Johnson by 1.4% during the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 9,588 shares of the company’s stock valued at $2,538,000 after purchasing an additional 131 shares during the period. Finally, Intesa Sanpaolo Wealth Management raised its stake in Johnson & Johnson by 1.3% during the 3rd quarter. Intesa Sanpaolo Wealth Management now owns 9,867 shares of the company’s stock valued at $2,612,000 after acquiring an additional 130 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.
Top Johnson & Johnson Stories
These are some of the JNJ stories that stood out recently:
- Positive Sentiment: The company submitted an FDA application to expand CAPLYTA’s use to bipolar I mania or mixed episodes, supported by two positive Phase 3 studies. Approval is not guaranteed, but another indication could broaden the drug’s growth potential. Article
- Neutral Sentiment: JPMorgan raised its JNJ price target to $300 from $285 but kept a “neutral” rating, signaling a higher valuation estimate without a change in its overall recommendation. Analyst rating
- Negative Sentiment: A Louisiana appeals court upheld a multimillion-dollar talc verdict and increased damages, reinforcing ongoing litigation exposure for J&J. Article
Wall Street Analyst Weigh In
Get Our Latest Stock Analysis on JNJ
Johnson & Johnson Stock Up 1.3%
Shares of JNJ opened at $270.54 on Friday. The firm’s 50 day moving average is $267.53 and its 200-day moving average is $250.98. The stock has a market capitalization of $651.27 billion, a PE ratio of 40.99, a P/E/G ratio of 2.72 and a beta of 0.22. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12 month low of $199.90 and a 12 month high of $290.25.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company’s revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the business earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities research analysts forecast that Johnson & Johnson will post 11.12 EPS for the current year.
Johnson & Johnson Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio is presently 81.21%.
Insider Buying and Selling
In other Johnson & Johnson news, EVP Elizabeth Forminard sold 13,072 shares of Johnson & Johnson stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total value of $3,717,546.08. Following the completion of the sale, the executive vice president directly owned 16,994 shares of the company’s stock, valued at approximately $4,832,923.66. The trade was a 43.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.16% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
Read More
- Five stocks we like better than Johnson & Johnson
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
